[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"visual-acuity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:visual-acuity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,78,119,146,184,208,229,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630651","phase-2-metric-optimized-spectacle-prescriptions-for-children-with-down-syndrome-100630651",false,"NCT07490444","Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome","Metric-derived Corrections Versus Clinically-derived Corrections for Children With Down Syndrome","Inclusion Criteria:\n\n* Down syndrome\n* Age 5 to 12 years\n* Ability to sit for study measures\n* Able to be dilated\n\nExclusion Criteria:\n\n* Nystagmus\n* History of Ocular or Refractive Surgery\n* Corneal or lenticular opacities\n* Ocular disease\n* Anisometropic or strabismic amblyopia\n* Contact allergy to aluminum","ALL","5 Years","12 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study seeks to determine whether glasses prescriptions determined from computer analysis of detailed images of the eyes provide better vision outcomes for children with Down syndrome than prescriptions determined using routine clinical methods.",[27,28],"Refractive Error Correction","Visual Acuity",[30,31,32,33,34],"Down syndrome","Children","Glasses","Spectacles","Vision","RECRUITING","2026-06-16",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2026-05-26",{"date":43,"type":21},"2028-05-01",{"name":45,"class":46},"Ohio State University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100635052","effectiveness-of-tdcs-in-paediatric-amblyopia-100635052","NCT07547670","Effectiveness of tDCS in Paediatric Amblyopia.","tDCS","Inclusion Criteria:\n\n* Children aged 4-14 years.\n* Strabismic amblyopia resistant to patching (PEDIG criteria).\n* Anisometropic amblyopia resistant to patching (PEDIG criteria).\n\nExclusion Criteria:\n\n* Ocular pathology.\n* Nystagmus.\n* Mental disability.\n* Cognitive delay.\n* Neurological problems incompatible with treatment.\n* Pacemakers.\n* Intracranial electrodes.\n* Implanted defibrillators.\n* Cranial pathologies.\n* Cranial lesions.\n* Withdrawal will occur upon adverse events, protocol deviation, refusal, or loss to follow-up.","4 Years","14 Years",{"count":58,"type":21},100,[60],"NA","The goal of this randomized, double-blind clinical trial is to determine whether transcranial direct current stimulation (tDCS) can effectively and safely improve vision in children aged 4-14 years with strabismic or anisometropic amblyopia that has not responded to conventional patching therapy.\n\nThe main questions it aims to answer are:\n\nDoes tDCS produce significant and sustained improvements in visual acuity, contrast sensitivity, and stereopsis in children with amblyopia?\n\nIs tDCS a safe, well-tolerated, and faster alternative or complementary treatment compared with standard occlusion therapy?\n\nDoes tDCS induce functional and structural changes in the visual cortex associated with increased neuroplasticity, including modulation of GABAergic activity?\n\nIf there is a comparison group:\n\nResearchers will compare active tDCS with sham (placebo) stimulation to see if active treatment leads to greater visual recovery and cortical changes than placebo.\n\nParticipants will:\n\nReceive several sessions of active or sham tDCS using low-intensity electrical stimulation applied to visual brain areas.\n\nUndergo standard visual assessments, including visual acuity, contrast sensitivity, and stereopsis.\n\nComplete neurophysiological and neuroimaging evaluations (EEG, pattern visual evoked potentials, and functional MRI).\n\nProvide biochemical measures related to GABA levels.\n\nThis study aims to validate tDCS as a non-invasive, child-friendly, and effective therapy that may overcome the limitations of patching and support its inclusion in paediatric clinical practice.",[63,64,28,65],"Amblyopia","Amblyopia Strabismic","Stereoscopic Vision",[53,67],"Ambyopia","NOT_YET_RECRUITING","2026-04-23",{"date":71,"type":39},"2026-04-29",{"date":73,"type":21},"2026-06-01",{"date":75,"type":21},"2029-08-31",{"name":77,"class":46},"Universidad de Murcia",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":47},"100609329","clinical-evaluation-of-low-contrast-visual-performance-and-low-light-phenomena-in-patients-with-various-intraocular-lens-implants-100609329","NCT07213167","Clinical Evaluation of Low Contrast Visual Performance and Low Light Phenomena in Patients With Various Intraocular Lens Implants","Clinical Evaluation of Low Contrast Defocus Curves, Low Light Photic Phenomena, and Dysphotopsia Profiles in Pseudophakic Patients","Inclusion Criteria:\n\n* Minimum 22 years of age\n* Bilateral pseudophakia, at least 3 months postoperative from IOL implantation, with one of the study IOL models in at least one eye.\n* Availability, willingness, and sufficient cognitive awareness to comply with examination procedures\n* Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries\n* Ability to understand and respond to a questionnaire in English\n\nExclusion Criteria:\n\n* Any clinically significant pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils.\n* Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)\n* Uncorrected distance visual acuity worse than 20\u002F25 in either eye\n* Prior corneal refractive surgery (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcomes are acceptable.\n* Posterior capsular opacification with grading worse than 1+\n* Ocular findings that may, in the opinion of the investigator, affect vision and\u002For contrast sensitivity","22 Years",{"count":87,"type":21},120,"1 Day","OBSERVATIONAL","The goal of this clinical investigation is to evaluate visual acuity and contrast sensitivity in low lighting conditions using several different testing devices, and measure nighttime side effects of intraocular lens (IOL) implants after cataract surgery.\n\nResearchers will compare the results for three different types of IOLs to see how each lens contributes to overall visual function, patient experience and satisfaction.\n\nParticipants will:\n\n* Complete two different questionnaires about their current vision\n* Undergo visual testing using several different devices",[92,93,28,94,95],"Dysphotopsia","Posterior Capsule Opacification","Visual Function","Contrast Sensitivity",[92,93,97,98,99,100,101,102,103,104,105,106,107,108,109],"Halometry","Manifold Vision Meter","PRVSQ","AIOLIS","TECNIS Eyhance IOL","TECNIS Symfony Optiblue IOL","TECNIS Odyssey IOL","Low Contrast","Defocus Curves","Low Light Photic Phenomena","Dysphotopsia Profiles","Pseudophakia","TECNIS 1-Piece","2026-03-31",{"date":112,"type":39},"2026-04-06",{"date":114,"type":39},"2025-09-24",{"date":116,"type":21},"2026-08",{"name":118,"class":46},"Dr. Daniel H. Chang, MD",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100620075","exploration-strategies-in-night-vision-sensors-100620075","NCT07352904","Exploration Strategies in Night Vision Sensors","STRAT-JVN","Inclusion Criteria:\n\n* Affiliated with social security;\n* Normal vision or vision corrected with lenses (far vision ≤ 0.03 log unit (≥ 9\u002F10) OD\u002FOG\u002Fbinocular);\n* No current or past ocular or binocular pathology: strabismus or amblyopia;\n* Signed non-objection form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Incapacitated adults;\n* Individuals who do not understand French (written or spoken).",true,"18 Years",{"count":129,"type":21},10,"The main objective of this clinical trial is to identify a variation in visual strategy characterized by both head movements and eye movements of healthy volunteers during a target detection task when images simulating night vision goggles (NVG) are presented, compared to a situation in which the images simulate a natural environment.\n\nTo highlight changes in environmental scanning with simulated images from NVG, objective measurements will be collected:\n\n* eye movements characterized by saccades (speed, latency, and number) for each stimulus\n* head movements (horizontal angle of the participant's head) for each stimulus and throughout the exposure\n\nParticipants sit facing a screen (9.90 m x 2.10 m) onto which a virtual scene is projected. The objective is to correctly identify, as quickly as possible, a target stimulus (represented by a tank) that may appear in the scene. They must use the directional arrows on a game controller to indicate whether the tank is moving to the left or to the right.\n\nThere are four visits involving four viewing conditions in which the task remains the same:\n\n* With restricted field of view and a normal scene.\n* Without restricted field of view and a scene simulating the vision obtained by NVGs.\n* With restricted field of view and a scene simulating the vision obtained by NVGs.\n* Without restricted field of view and a normal scene. Regarding the content of the scene, half of the tests in each visit involve a so-called poor scene when fog is simulated, or an enriched scene when there is no fog. Each visit lasts approximately one hour and thirty minutes.",[28],[133,134,135,136],"visual strategy","Night Vision Goggles","eyetracking","visual fatigue","2026-01-15",{"date":139,"type":39},"2026-01-20",{"date":141,"type":21},"2026-02-01",{"date":143,"type":21},"2026-12-25",{"name":145,"class":46},"Direction Centrale du Service de Santé des Armées",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":126,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":156,"conditions":157,"keywords":167,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":47},"100599518","natural-history-study-of-inherited-retinal-diseases-100599518","NCT07085533","Natural History Study of Inherited Retinal Diseases","Color Vision Loss Progression in IRD Patients: Retinal Structural Changes Correlations, and a Novel Color Discrimination Test for Extreme Low Vision Patients","MojiLVCDT","Inclusion Criteria:\n\n1. Color Perception and Communication Ability Participants must have the ability to verbally identify or describe colors and test stimuli. This requires adequate cognitive and communicative capacity to understand instructions and respond appropriately during color vision testing.\n2. Diagnosis of Inherited Retinal Dystrophy (IRD Group Only) Participants assigned to the IRD group must have a confirmed clinical diagnosis of an inherited retinal dystrophy\n3. No Evidence of Inherited Retinal Disease (Control Group Only)\n\nParticipants in the control group must have:\n\n* No known history or clinical evidence of inherited retinal degeneration\n* Normal retinal health or only non-retinal ocular conditions not affecting retinal function (e.g., mild cataract, corrected refractive error)\n* Normal or expected-normal color vision\n\nExclusion Criteria:\n\n1. Non retinal causes of color vision loss\n\n   * Optic neuropathies (e.g., optic neuritis, glaucoma related optic nerve damage)\n   * Cortical vision impairments affecting color perception\n   * Any other neurological or optic nerve pathology causing color vision deficiency\n2. Psychological or cognitive conditions affecting color perception or communication\n\n   * Severe developmental delays\n   * Cognitive impairments interfering with ability to comprehend or reliably perform color vision tests\n   * Psychiatric conditions that impair visual interpretation or reliable testing\n3. Prior treatment with potential transient effects on the retina\n\n   * Recent retinal surgery\n   * Recent drug therapy affecting retinal structure or function\n   * Any acute intervention that might confound the correlation analyses due to lack of a stable baseline",{"count":155,"type":21},200,"This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal Dystrophies (IRDs). The study will recruit approximately 200 subjects, encompassing a heterogeneous population of IRD patients-spanning a range of genotypes and clinical severities-as well as control participants devoid of retinal pathology. All enrolled individuals will undergo a standardized battery of evaluations, including quantitative color vision assessment, best-corrected visual acuity (BCVA) determination, and advanced multimodal retinal imaging.\n\nThe principal aim is to characterize the relationship between impairments in color discrimination and morphologic disruptions within the outer retinal layers, with particular emphasis on the continuity and reflectivity of the ellipsoid zone (EZ)-historically referred to as the inner segment\u002Fouter segment (IS\u002FOS) junction-assessed through spectral-domain optical coherence tomography (SD-OCT). Further, the study will explore associations between chromatic perceptual deficits and underlying genetic mutations, mutation patterns specific to IRD subtypes, and the influence of patient age on the severity and progression of color vision loss.\n\nA key secondary objective is the clinical appraisal and validation of a novel diagnostic modality, the Moji Low-Vision Color Discrimination Test (Moji Test), which is specifically engineered to quantify residual color perception in individuals with advanced central visual impairment. The test's discriminatory capacity will be benchmarked against established color vision testing paradigms to assess its reliability, clinical sensitivity, and suitability for implementation in populations with severe visual acuity reduction.\n\nBy incorporating a genetically and phenotypically diverse IRD cohort, the study is designed to enable granular, stratified analyses that will refine the understanding of structural-functional correlations in hereditary retinal disease. The inclusion of a control group with preserved retinal architecture and normal color vision function will provide essential normative baselines for comparative evaluation and statistical inference.",[158,159,160,161,162,163,28,164,165,166],"Retinal Dystrophies","Color Vision Defects","Vision Disorders","Macular Degeneration","Achromatopsia","Optical Coherence Tomography (OCT)","Genotype","Mutation","Phenotype",[168,169,170,171,172,173],"observational","IRD","ultra low vision","inherited retinal disease","color vision","color test","2025-12-03",{"date":176,"type":39},"2025-12-10",{"date":178,"type":39},"2025-07-20",{"date":180,"type":21},"2027-09-28",{"name":182,"class":183},"Zhongmou Therapeutics","INDUSTRY",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":126,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":191,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":192,"conditions":193,"keywords":198,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100611430","assessing-the-turkish-ddivat-for-visual-acuity-measurement-100611430","NCT07240480","Assessing the Turkish DDIVAT for Visual Acuity Measurement","Validation of the Turkish Version of the DDIVAT Visual Acuity Measuring Device in a Turkish-speaking Population","Inclusion Criteria:\n\n* Adults aged 18 years or older\n\nTurkish-speaking individuals able to understand the study purpose\n\nWillingness to participate and provide written informed consent\n\nParticipants with or without refractive errors (e.g., myopia, hyperopia, astigmatism)\n\nExclusion Criteria:\n\n* Age below 18 years\n\nIndividuals unable to complete visual acuity testing\n\nPresence of severe ocular pathology (e.g., corneal opacity, retinal detachment) that prevents accurate measurement\n\nCognitive or communication difficulties preventing informed consent",{"count":155,"type":21},"The goal of this observational methodological study is to validate the Turkish version of the DDIVAT visual acuity measuring device in a Turkish-speaking adult population.\n\nThe main questions it aims to answer are:\n\nDoes the Turkish version of the DDIVAT provide reliable and valid visual acuity measurements in Turkish speakers?\n\nAre the results of the DDIVAT comparable to those obtained with the standard Snellen chart used in clinical practice?\n\nResearchers will compare DDIVAT visual acuity test results with Snellen chart results to see if both methods produce consistent measurements.\n\nParticipants will:\n\nBe adults aged 18 years or older, including both patients and healthy volunteers.\n\nUndergo visual acuity testing using the DDIVAT system displayed on a smart TV connected to the university server.\n\nHave their visual acuity re-measured using the standard Snellen optotype under the same conditions.\n\nNo medication or invasive procedure will be used. The study carries no risk to participants.",[28,194,195,196,197],"Refractive Errors","Myopia","Hyperopia","Astigmatism",[28,194],"2025-11-26",{"date":201,"type":39},"2025-12-04",{"date":203,"type":21},"2025-12-01",{"date":205,"type":21},"2026-05-31",{"name":207,"class":46},"Trakya University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":126,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":47},"100549229","evaluation-of-a-digital-visual-acuity-device-vs-standard-visual-acuity-measurements-100549229","NCT06431295","Evaluation of a Digital Visual Acuity Device vs. Standard Visual Acuity Measurements","Human Performance Evaluation of a Digital Visual Acuity Device: Visual Acuity-001","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) who come to Ophthalmology Clinic.\n* Willing and able to provide consent.\n\nExclusion Criteria:\n\n* Individuals \\\u003C 18 years of age.\n* Unable to provide consent.",{"count":216,"type":21},150,[60],"The purpose of this research is to validate and determine the accuracy of the experimental device when measuring visual acuity versus our standard visual acuity measurements and to gather voice recordings of letters to help build a special system that recognizes spoken letters.",[28],"2025-11-17",{"date":222,"type":39},"2025-11-19",{"date":224,"type":21},"2027-10-01",{"date":226,"type":21},"2029-06",{"name":228,"class":46},"Mayo Clinic",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":237,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":240,"conditions":241,"keywords":258,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100590537","project-icope-brazil-assessment-of-intrinsic-capacity-in-brazilian-older-adults-100590537","NCT06968702","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Brazilian Older Adults","Project ICOPE Brazil: Assessment of Intrinsic Capacity in Older Adults as a Basis for Implementation of the WHO ICOPE Strategy in the Unified Health System.","ICOPE-BR","Inclusion Criteria:\n\n* People aged ≥ 60 years, with no age limit;\n* Being registered (with available contact information) in the participating health care units;\n* Being available to go in person to the data collection sites for the assessments.\n\nExclusion criteria\n\n* Inability to access the data collection site;\n* Severe neurologic and\u002For cognitive impairments that preclude interaction with the evaluators to complete the proposed tests and data collections;\n* Advanced serious illness or under palliative care:\n\nClinical Frailty Scale (CFS)20 score of 8 (severely frail) or 9 (terminally ill).","60 Years",{"count":239,"type":21},3838,"The ICOPE Brazil study aims to understand aging trajectories in Brazil, especially healthy aging trends based on intrinsic capacity, a collective of mental and physical capacities one may have to maintain their functional ability to execute daily life activities. Tests and questionnaires will be applied to collect data on mobility capacity, cognitive capacity, nutritional status, vision, and hearing (sensorial) capacities, and mental health. These assessments are in consonance with what the World Health Organization proposed in the Integrated Care for Older People Program (ICOPE). Participants will be followed up for three years, and the primary outcomes of interest are loss of intrinsic capacity, mobility impairment, cognitive impairment, incident depressive symptoms, loss of functional ability, incident frailty, incident sarcopenia, incident falls, hospitalization, multimorbidity, and mortality.",[242,243,244,245,246,247,248,249,250,251,28,252,253,254,255,256,257],"Intrinsic Capacity","Frailty","Aging","Healthy Aging","Functional Ability","Mobility and Independence","Cognitive Ability, General","Cognitive Impairment","Sensory Hearing Loss","Sensory Deficits","Visual Impairment","Mood Disorders","Depressive Symptoms","Vitality","Nutritional Risk","Nutrition Assessment",[259,246,260,261,262,243,249,263,264,255,265,266,267,268],"Instrinsic Capacity","ICOPE","Aging trends","Older Adults","Mobility","Sensory","Psychological","Cohort","healthy aging","public health","2025-05-05",{"date":271,"type":39},"2025-05-13",{"date":273,"type":21},"2025-05-15",{"date":275,"type":21},"2029-11",{"name":277,"class":46},"University of Sao Paulo",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100578319","phase-2-evaluating-efficacy-and-safety-of-oral-melatonin-in-acute-central-serous-chorioretinopathy-100578319","NCT06809751","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy (CSCR): a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks\n2. Patients with minimum age of 18 years old\n3. Consent to participate in the study\n\nExclusion Criteria:\n\n1. A history of vitrectomy\n2. A history of laser surgery in the eye being studied in the past 3 months\n3. A history of anti-VEGF injection in the eye being studied in the past 3 months\n4. History of patient suspicious for choroidal neovascularization (CNV)\n5. Pregnant or nursing patients\n6. Patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition\n7. Patients participating in any other investigational drug study\n8. Inability to obtain OCT photographs",{"count":286,"type":21},48,[24,288],"PHASE3","The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:\n\n1. How does melatonin affect central macula thickness in CSCR?\n2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.\n\nParticipants will:\n\n1. Take melatonin or placebo twice a day for one month\n2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests\n3. Keep a diary of their symptoms",[291,292,293,28,294],"Central Serous Chorioretinopathy","Melatonin","Ocular Diseases","Macula Abnormality","2025-01-30",{"date":297,"type":39},"2025-02-05",{"date":299,"type":21},"2025-02-01",{"date":301,"type":21},"2025-06-01",{"name":303,"class":46},"Mohsen Pourazizi"]